이스라엘 - 영어 - Ministry of Health

abic marketing ltd, israel - teriparatide as acetate - solution for injection - teriparatide as acetate 250 mcg/ml - teriparatide - treatment of postmenopausal women with osteoporosis at high risk for fracture:teriparatide teva is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis, teriparatide teva increases bmd reduces the risk of vertebral and nonvertebral fractures . increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture :teriparatide teva is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy . treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture:teriparatide teva is indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy

요르단 - 영어 - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة المتحدة لصناعة الأدوية - united pharmaceutical manufacturing co. ltd. - prasugrel as hcl 10 mg - as hcl 10 mg

요르단 - 영어 - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة المتحدة لصناعة الأدوية - united pharmaceutical manufacturing co. ltd. - prasugrel as hcl 5 mg - as hcl 5 mg

이스라엘 - 영어 - Ministry of Health

novartis israel ltd - deferasirox - tablets dispersible - deferasirox 125 mg - deferasirox - deferasirox - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusionalhaemosiderosis) in adult and pediatric patients (aged 2 years and over).exjade is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [lic] ≥5 mg fe/g dry weight [dw] or serum ferritin consistently >800 μg/l).lic is the preferred method of iron overload determination and should be used wherever available

이스라엘 - 영어 - Ministry of Health

novartis israel ltd - deferasirox - tablets dispersible - deferasirox 500 mg - deferasirox - deferasirox - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusionalhaemosiderosis) in adult and pediatric patients (aged 2 years and over).exjade is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [lic] ≥5 mg fe/g dry weight [dw] or serum ferritin consistently >800 μg/l).lic is the preferred method of iron overload determination and should be used wherever available

이스라엘 - 영어 - Ministry of Health

novartis israel ltd - deferasirox - tablets dispersible - deferasirox 250 mg - deferasirox - deferasirox - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusionalhaemosiderosis) in adult and pediatric patients (aged 2 years and over).exjade is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [lic] ≥5 mg fe/g dry weight [dw] or serum ferritin consistently >800 μg/l).lic is the preferred method of iron overload determination and should be used wherever available

이스라엘 - 영어 - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - film coated tablets - eletriptan hydrobromide 24.242 mg - eletriptan - acute treatment of the headache phase of migraine attacks, with or without aura.

이스라엘 - 영어 - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - film coated tablets - eletriptan hydrobromide 48.485 mg - eletriptan - acute treatment of the headache phase of migraine attacks, with or without aura.

이스라엘 - 영어 - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - film coated tablets - eletriptan hydrobromide 96.97 mg - eletriptan - acute treatment of the headache phase of migraine attacks, with or without aura.

이스라엘 - 영어 - Ministry of Health

novartis israel ltd - crizanlizumab - concentrate for solution for infusion - crizanlizumab 10 mg/ml - crizanlizumab - adakveo is indicated to reduce the frequency of vasoocclusive crises (vocs) in adults and pediatric patients aged 16 years and older with sickle cell disease.